Results for tag: "Pegfilgrastim Biosimilars"

Pegfilgrastim is a long-acting form of the drug filgrastim, which stimulates the growth of white blood cells and is thus used to decrease the incidence of infection in patients undergoing chemotherapy. As part of the broader market of oncology drugs, biosimilars for pegfilgrastim hold an important position in supportive cancer care. After the patent expiration of the reference product, biosimilars have been developed to offer comparable safety and efficacy at a potentially lower cost. The introduction of biosimilars contributes to the sustainability of healthcare systems by providing additional treatment options and promoting market competition. The development of pegfilgrastim biosimilars adheres to stringent regulations to ensure they meet the standards for pharmacokinetic and pharmacodynamic properties, clinical efficacy, and safety that are comparable to the original biologic product. In oncology, the availability of these biosimilars is critical for the management of neutropenia, a common side effect of chemotherapy that can lead to life-threatening infections. Multiple companies have entered the pegfilgrastim biosimilar market, enhancing the therapeutic landscape for patients with cancer. Notable players include Amgen, which produces the reference product Neulasta, as well as Mylan, Coherus BioSciences, Sandoz, a division of Novartis which provides a product named Ziextenzo, and Pfizer, with their product Nyvepria. These companies and others in the field are engaged Show Less Read more